NorthWest Biotherapeutics Inc (NWBO)

[FatCat_Banker]

The negative possibility is that it is terminated due to futility.

I'm not sure what else you want as the good possibilities range boundlessly, and the negative is terminal and singular.

These studies could prove to be inconclusive. Even in such an event, a continuation could still be recommended as safety, the primary consideration, is a foregone conclusion at this point.

If you track these posts prior, they detail the consistency of the trials. It is complex in nature, as it should be, and will have responsiveness seen in aspects and not in others. This is due, as noted by prior posts, to the ambiguous nature of GBM. It will be the majority that rules. Mind you, a third of prior efficacy needs to be seen for a positive ruling and the DMC is likely to rule in favor, within the ethics guidelines, in severe conditions such as these.

I'm sorry for your loss.